13F Data
13F filer · CIK 1892770

Knott David M Jr

SYOSSET, NY · filing since Q4 2021 · last filing Aug 12, 2026
Reported value
$189.2M
+$21.1M vs prior
Positions
84
New / sold out
11 / 12
Added / reduced
16 / 4
Turnover
6.3%
buys $11.3M · sells $12.9M
Top-10 weight
62.8%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewCatalyst Pharmaceuticals, Inc.+114,000–+$3.6M
NewSpruce Biosciences, Inc.+20,000–+$1.1M
AddedCullinan Therapeutics, Inc.+44,982+185.9%+$819.1K
AddedMadrigal Pharmaaceuticals, Inc.+1,000+50.0%+$537.0K
NewDuPont de Nemours, Inc.+3,767–+$511.0K
NewInsmed Incorporated+4,253–+$453.5K
NewLB Pharmaceuticals, Inc.+12,965–+$420.8K
NewCareDx, Inc.+13,630–+$388.5K
NewQ32 Bio Inc+30,412–+$387.4K
AddedTravere Therapeutics, Inc.+6,649+4.7%+$377.7K
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outCatalyst Pharmaceuticals, Inc.-120,000-100.0%$-3.0M
Sold outArcellx Inc-19,433-100.0%$-2.2M
Sold outCytokinetics, Incorporated-23,644-100.0%$-1.6M
Sold outCentessa Pharmaceuticals PLC-39,000-100.0%$-1.5M
ReducedTG Therapeutics, Inc.-23,162-25.7%$-1.3M
ReducedBristol-Myers Squibb Company-11,622-85.3%$-669.7K
Sold outADMA Biologics, Inc.-60,200-100.0%$-542.4K
Sold outBiohaven Pharmaceutical Holding Co. Ltd-60,720-100.0%$-513.7K
ReducedJPMJPMorgan Chase & Co.-1,379-7.1%$-451.4K
Sold outEvolus, Inc.-99,338-100.0%$-408.3K
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2021: $289.0MQ1 2022: $296.0MQ2 2022: $218.6MQ3 2022: $218.0MQ4 2022: $247.8MQ1 2023: $244.5MQ2 2023: $242.6MQ3 2023: $254.4MQ4 2023: $261.6MQ1 2024: $282.8MQ2 2024: $250.6MQ3 2024: $284.6MQ4 2024: $276.5MQ1 2025: $212.0MQ2 2025: $220.6MQ3 2025: $248.0MQ4 2025: $215.9MQ1 2026: $168.0MQ2 2026: $189.2M
Q4 2021Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Alphabet Inc-Cl CCOMMON91,420$32.3M17.07%
2Apollo Global Management, Inc.COMMON225,000$26.6M14.07%
3Syndax Pharmaceutical, Inc.COMMON437,245$9.6M5.05%
4Xeris Biopharma Holdings, Inc.COMMON1,060,000$8.4M4.44%
5Travere Therapeutics, Inc.COMMON147,282$8.4M4.42%
6Protagonist Therapeutics, IncCOMMON63,000$7.7M4.08%
7Bridgebio Pharma, Inc.COMMON92,850$6.9M3.66%
8Iovance Biotherapeutics, Inc.COMMON1,600,000$6.7M3.52%
9Alkermes PLCCOMMON121,759$6.4M3.37%
10JPMJPMorgan Chase & Co.18,098$5.9M3.13%
74 more rows. Subscribe for $29/month to see every row, download the data and use the API.